German site
Pharmanovia acquires exclusive rights to novel antipsychotic treatment
- SECOND PRODUCT RIGHTS COMPLETES OUR ACQUISITION OF CSL SEQIRUS’ AUSTRALIAN BASED CNS PORTFOLIO AND FURTHER STRENGTHENS PHARMANOVIA’S FOOTHOLD IN AUSTRALIA AND NEW ZEALAND
- DEAL ADDS A NEW CHEMICAL ENTITY IN AUSTRALIA TO OUR CNS PORTFOLIO
BASILDON, UK, 1st April 2025
Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced the expansion of its CNS portfolio with a new licensing agreement for Reagila® (cariprazine) a third-generation atypical antipsychotic indicated for the treatment of schizophrenia in adult patients1.
The agreement will see Pharmanovia acquire rights to all potential indications from existing licensee, CSL Seqirus in Australia and New Zealand, working closely with originator Gedeon Richter on supply and future development opportunities.
Gedeon Richter will remain the Marketing Authorisation holder (MAH), and Pharmanovia will take responsibility for commercial activity in the region.
Schizophrenia affects approximately 1 in 222 adults worldwide and those living with Schizophrenia are 2 to 3 times more likely to die earlier than the general population, according to the World Health Organization2.
Pharmanovia CEO, James Burt commented: “We’re delighted to expand our CNS portfolio with a novel treatment for those living with schizophrenia. Our Australian CNS sales and marketing team already have a strong understanding and knowledge of Reagila® (cariprazine), meaning we’re in a position to support this product from the outset.
“We’re also excited about the opportunities we have in different indications and for lifecycle management development and we look forward to evaluating these further with Gedeon Richter.”
Danielle Dowell, CSL Seqirus’ Executive Director for Commercial Operations APAC, added: “Pharmanovia has strong capabilities and presence both in ANZ and in CNS and has already made an impressive start with Xadago® which they acquired from us in 2024.
“We fully expect them to continue to leverage their capabilities and platform to reach even more patients living with Central Nervous System disorders.”
-Ends-
Notes to editors
For further information, please contact:
Alison Dyson, Director of Communications, Pharmanovia
07912887250/ communications@pharmanovia.com
About Pharmanovia
Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.
We do this by rediscovering, repurposing or re-engineering iconic brands to improve patient outcomes and experiences both through in-house development and through strategic partnerships on established and novel medicines.
Our diverse and growing team operate in over 160 countries across the globe, delivering high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology.
About CSL Seqirus
CSL Seqirus is part of CSL (ASX: CSL). As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. CSL Seqirus offers a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world.
In Australia, CSL Seqirus operates the only local manufacturing facility for seasonal and pandemic influenza vaccine and produces a range of unique medicines in the national interest, including antivenoms and the world’s only human vaccine for Q fever. Our commitment to Australia’s health also extends to providing access to paediatric and adult vaccines, and innovative pharmaceuticals for patients living with allergies, cardiovascular disease, severe pain, dry eye disease, iron deficiency, kidney diseases, rare diseases and neurological conditions.
References
1 SPC, EMA website, last accessed 12.3.2025 – https://www.ema.europa.eu/en/documents/product-information/reagila-epar-product-information_en.pdf
2 WHO fact sheet, Schizophrenia, last accessed 12.3.2025 –https://www.who.int/news-room/fact-sheets/detail/schizophrenia